CANCER DIAGNOSIS AND THERAPY BASED ON MUTATIONS IN TGF-BETA RECEPTORS

摘要

This invention is based on the discovery that the type II TGF beta receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25 % of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.